|
gptkbp:instance_of
|
gptkb:biotechnology
|
|
gptkbp:acquisition
|
gptkb:Cure_Vac_AG
Provenance Biopharmaceuticals
Sirna Therapeutics
|
|
gptkbp:can_lead_to
|
ALN-AGT
ALN-AGT-02
ALN-AGT-03
ALN-APC
ALN-APC-02
ALN-APC-03
ALN-CCP
ALN-CCP-02
ALN-CCP-03
ALN-HTT
ALN-HTT-02
ALN-HTT-03
ALN-PCS
ALN-PTC
ALN-PTC-02
ALN-PTC-03
ALN-TSEN
ALN-TSEN-02
ALN-TSEN-03
ALN-AT3
ALN-AT3-02
ALN-AT3-03
ALN-TTRsc
|
|
gptkbp:ceo
|
Yvonne Greenstreet
|
|
gptkbp:clinical_trial
|
Phase 1
Phase 2
Phase 3
Phase 3 trials
Phase 1 trials
Phase 2 trials
|
|
gptkbp:collaboration
|
gptkb:University_of_Massachusetts_Medical_School
gptkb:Harvard_University
gptkb:MIT
|
|
gptkbp:employees
|
over 500
~800 (2021)
|
|
gptkbp:focus
|
RNA interference
|
|
gptkbp:focuses_on
|
RNA interference
|
|
gptkbp:founded
|
gptkb:2002
|
|
gptkbp:founded_by
|
gptkb:John_Maraganore
|
|
gptkbp:founded_in
|
gptkb:2002
|
|
gptkbp:founder
|
gptkb:John_Maraganore
|
|
gptkbp:headquarters
|
gptkb:Cambridge,_Massachusetts
|
|
gptkbp:healthcare
|
gptkb:2018
gptkb:2019
gptkb:2020
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Alnylam Pharmaceuticals
|
|
gptkbp:investment
|
Venture capital
|
|
gptkbp:market_cap
|
$10 billion (2021)
|
|
gptkbp:notable_achievement
|
First RNAi therapeutic approved by FDA
Pioneer in RNAi technology
|
|
gptkbp:notable_products
|
gptkb:Leqvio
Givlaari
Onpattro
|
|
gptkbp:partnership
|
gptkb:Sanofi
gptkb:Regeneron_Pharmaceuticals
|
|
gptkbp:product
|
Givlaari
Onpattro
Oxlumo
|
|
gptkbp:research_areas
|
cardiovascular diseases
neurological diseases
metabolic diseases
|
|
gptkbp:research_focus
|
rare diseases
genetic diseases
cardiovascular diseases
metabolic diseases
|
|
gptkbp:revenue
|
$300 million (2020)
|
|
gptkbp:stock_symbol
|
ALNY
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:website
|
www.alnylam.com
|
|
gptkbp:bfsParent
|
gptkb:Biogen
|
|
gptkbp:bfsLayer
|
4
|